All In Biotech

Drug Trial Radar · NCT05046132

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

A Randomized, Double-Blind, 3-arm, Parallel Group, Placebo- and Positive-controlled Study to Investigate the Effects of Setmelanotide on QTc Interval in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

77

Actual

Start

Aug 5, 2021

Primary completion

Apr 7, 2022

Study completion Apr 7, 2022

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a double-blind, randomized, placebo- and positive-controlled, parallel group, 3-arm study that assessed the potential for therapeutic and supratherapeutic concentrations of setmelanotide to affect the QTc corrected by the Fredericia method (QTcF) interval.

Conditions

  • Healthy

Interventions

  • SetmelanotideDrug

    Administered once daily via SC injection.

  • MoxifloxacinDrug

    Moxifloxacin capsules via oral administration.

  • Oral PlaceboDrug

    Placebo capsules via oral administration.

  • SC PlaceboDrug

    Placebo via SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hours (hrs) postdose
  2. Setmelanotide Concentration-related Placebo-corrected CHFB in QTcF at Day 16Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel Early Phase Clinical Unit (Los Angeles)

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.